CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs ...

Viking Therapeutics (NasdaqCM:VKTX) experienced a share price increase of 10% last week, coinciding with the announcement of a multi-year manufacturing agreement with CordenPharma for its V2735 ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

After earmarking a major chunk of change last year to bulk up in peptide production, European CDMO CordenPharma is putting ...

CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

CordenPharma has unveiled plans for a strategic investment exceeding 1 billion euros ($1.1 billion) to enhance its peptide ...